Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Musa Yilmaz

Showing results (151-160 of 160) with videos related to

Pageof 16
Sort By:
You have reached the last page of results.This site can display upto 160 results.
American Journal of Hematology|April 26, 2026
Cladribine With Low-Dose Cytarabine and Venetoclax Alternating With Azacitidine and Venetoclax for Newly Diagnosed Acute Myeloid LeukemiaTapan M Kadia, Alex Bataller, Alexandre Bazinet, et al.
JAMA Oncology|June 10, 2021
Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 TrialNitin Jain, Michael Keating, Philip Thompson, et al.
Cancer|March 19, 2021
Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemiaElias Jabbour, Koji Sasaki, Nicholas J Short, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 13, 2025
Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients With Isocitrate Dehydrogenase-Mutated AMLCourtney D DiNardo, Jennifer Marvin-Peek, Sanam Loghavi, et al.
American Journal of Hematology|December 2, 2020
Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortalityAbhishek Maiti, Wei Qiao, Koji Sasaki, et al.
Blood Advances|April 1, 2021
Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemiaAbhishek Maiti, Courtney D DiNardo, Sa A Wang, et al.
Cancer|November 25, 2024
Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemiaWei-Ying Jen, Jennifer Marvin-Peek, Hagop M Kantarjian, et al.
Leukemia|February 25, 2025
Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemiaCourtney D DiNardo, Wei-Ying Jen, Koichi Takahashi, et al.
The Lancet. Haematology|September 8, 2020
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trialCourtney D DiNardo, Abhishek Maiti, Caitlin R Rausch, et al.
Nature Medicine|January 19, 2023
Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trialsTimothy A Yap, Naval Daver, Mikhila Mahendra, et al.
Pageof 16

Showing results (151-160 of 160) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 160 results.
American Journal of Hematology|April 26, 2026
Cladribine With Low-Dose Cytarabine and Venetoclax Alternating With Azacitidine and Venetoclax for Newly Diagnosed Acute Myeloid LeukemiaTapan M Kadia, Alex Bataller, Alexandre Bazinet, et al.
JAMA Oncology|June 10, 2021
Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 TrialNitin Jain, Michael Keating, Philip Thompson, et al.
Cancer|March 19, 2021
Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemiaElias Jabbour, Koji Sasaki, Nicholas J Short, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 13, 2025
Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients With Isocitrate Dehydrogenase-Mutated AMLCourtney D DiNardo, Jennifer Marvin-Peek, Sanam Loghavi, et al.
American Journal of Hematology|December 2, 2020
Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortalityAbhishek Maiti, Wei Qiao, Koji Sasaki, et al.
Blood Advances|April 1, 2021
Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemiaAbhishek Maiti, Courtney D DiNardo, Sa A Wang, et al.
Cancer|November 25, 2024
Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemiaWei-Ying Jen, Jennifer Marvin-Peek, Hagop M Kantarjian, et al.
Leukemia|February 25, 2025
Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemiaCourtney D DiNardo, Wei-Ying Jen, Koichi Takahashi, et al.
The Lancet. Haematology|September 8, 2020
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trialCourtney D DiNardo, Abhishek Maiti, Caitlin R Rausch, et al.
Nature Medicine|January 19, 2023
Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trialsTimothy A Yap, Naval Daver, Mikhila Mahendra, et al.
Pageof 16